Sign Up
OverviewAPI
The biotech industry is experiencing a downturn with funding challenges, IPO dry spells, and a funding squeeze. However, there is hope for a stronger investment climate in 2024. Thermo Fisher's warning on a funding squeeze in the biotech sector has led to a decline in demand for its services and a decline in shares of rivals. Billionaire twins Thomas and Andreas Struengmann are reducing their stake in BioNTech SE as demand for the Covid-19 vaccine decreases, indicating a shift in investor focus. The Struengmanns are also involved in other investments, such as the buyout of Schuelke & Mayr GmbH.

Ask a question